Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2012.06.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular dynamics simulations of the secondary-binding site in disaccharide-modified glycopeptide antibiotics.
Sci Rep
April 2022
Department of Chemistry, Howard University, Washington, DC, 20059, USA.
Oritavancin is a semisynthetic glycopeptide antibiotic used to treat severe infections by multidrug-resistant Gram-positive pathogens. Oritavancin is known to be a thousand times more potent than vancomycin against Gram-positive bacteria due to the additional interactions with bacterial peptidoglycan (PG) facilitated by a secondary-binding site. The presence of this secondary-binding site is evident in desleucyl-oritavancin, an Edman degradation product of oritavancin, still retaining its potency against Gram-positive bacteria, whereas desleucyl-vancomycin is devoid of any antimicrobial activities.
View Article and Find Full Text PDFGenomic-Led Discovery of a Novel Glycopeptide Antibiotic by DSM 45129.
ACS Chem Biol
May 2021
Department of Biotechnology and Life Sciences, University of Insubria, via J. H. Dunant 3, 21100 Varese, Italy.
Glycopeptide antibiotics (GPAs) are last defense line drugs against multidrug-resistant Gram-positive pathogens. Natural GPAs teicoplanin and vancomycin, as well as semisynthetic oritavancin, telavancin, and dalbavancin, are currently approved for clinical use. Although these antibiotics remain efficient, emergence of novel GPA-resistant pathogens is a question of time.
View Article and Find Full Text PDFMicrobiologic factors affecting Clostridium difficile recurrence.
Clin Microbiol Infect
May 2018
Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, UK; Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, UK. Electronic address:
Background: Recurrent Clostridium difficile infection (rCDI) places a huge economic and practical burden on healthcare facilities. Furthermore, rCDI may affect quality of life, leaving patients in an rCDI cycle and dependant on antibiotic therapy.
Aims: To discuss the importance of microbiologic factors in the development of rCDI.
Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?
Curr Opin Infect Dis
April 2017
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Purpose Of Review: Skin and soft tissue infections (SSTIs) are prevalent in the obese population, with rising trend expected. Although numerous antibiotics are available for the prevention and treatment of SSTIs, their characterization in obese patients is not a regulatory mandate. Consequently, information that carries importance for optimizing the dosing regimen in the obese population may not be readily available.
View Article and Find Full Text PDFSafety profiles of old and new antimicrobials for the treatment of MRSA infections.
Expert Opin Drug Saf
December 2016
a Infectious Diseases Division , Santa Maria Misericordia Hospital, Udine , Italy.
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of severe nosocomial and community-acquired infections. Various adverse effects have been associated with compounds that are commonly used in the treatment of MRSA.
Areas Covered: Prolonged use of high-dose vancomycin has been linked with nephrotoxicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!